The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Fiscal cliff worries for 2021? Overstated

Mon, 26th Oct 2020 11:37

* European shares down 0.7% but off opening lows

* Tech giant SAP dumps targets, shares tank

* Upbeat vaccine development lifts AstraZeneca
Welcome to the home for real-time coverage of markets brought to
you by Reuters reporters. You can share your thoughts with us at
markets.research@thomsonreuters.com

FISCAL CLIFF WORRIES FOR 2021? OVERSTATED (1137 GMT)

A fiscal cliff might be possible in 2021 in Europe as
governments will scale back stimulus plans currently in place to
fight the economic impact of the virus.

Data available is probably not enough for a straight answer
on such a risk, but UBS started crunching some numbers and gave
some interesting insights.

“First, the draft plans show budget deficits declining in
2021 in all countries except for Estonia, which would bring the
Eurozone deficit down to 5.9% of GDP from 8.8% this year,” a UBS
research note says.

“Underlying the budget improvement is a projected return to
positive GDP growth in all countries,” it adds. For Spain,
France and Italy, growth projections in the draft budgets are
more optimistic than the latest IMF World Economic Outlook.

Looking at the structural budget balances that exclude the
impact of stronger growth as well as one-off/temporary factors,
fiscal tightening amounts to just 0.1% of GDP for 2021, compared
with 2.2% projected by the IMF, according to UBS.

The fiscal stance in 2021 is also impacted by spending of
grants from the EU recovery fund. “Assuming that 10% of the
grants from the EU recovery fund are spent in 2021, this would
imply a fiscal impulse of 0.3% of Eurozone GDP.”

(Stefano Rebaudo)

*****

TOWER POWER (1001 GMT)

Equities in Europe have recovered from early lows and while
that may be due to underlying hopes the virus won't derail the
recovery, an outperformance of telco stocks is also
playing a part.

The sector is buoyed after Cellnex announced its
latest M&A move on Friday in a deal that highlights not only the
tower operator's successful acquisition strategy but also the
opportunity for traditional telecoms to monetise on their tower
assets.

Barclays estimates that 60% of towers in Western Europe are
still owned by operators and notes increasing commentary from
larger operators around exploring options for infrastructure.

"We continue to argue it makes sense to sell towers and
reallocate capital to other areas... Retaining minority stakes,
such as in the potential Play-Cellnex deal, allows operators to
participate in future upside that they are unlikely to realise
standalone," Barclays says.

On Friday Cellnex agreed to buy a 60% stake in the cellphone
tower unit of Play.

Telecoms were last leading sectoral gainers in
Europe, up 0.3%, with Cellnex leading the way, up 2.6%.

(Danilo Masoni)

*****

ANALYSTS’ MIXED VIEWS AFTER S&P MOVE ON ITALY (0909 GMT)

Probably many investors are wondering if S&P upgrading
Italy’s outlook is a "once and in a lifetime" move or a vote of
confidence on an enhanced European integration, which is getting
traction following ECB measures and the proposal of a EU
recovery fund.

Analysts’ views are mixed on the matter, but there’s no
doubt the rating agency action took investors by surprise as
10-year Btp yields are down 8 basis points this morning.

S&P said Italy's outlook balances the negative consequences
of the coronavirus pandemic on public finances against the
extraordinary policy response by the European Central Bank.

S&P move “confirms how creditworthiness really depends on
funding costs more than anything else,” a Citi research note
says.

But more headwinds might emerge “with poor absorption rate
of the EU funds and/or the crystallization of the Covid
government guarantees,” it adds.

Besides, some sort of debt consolidation might be necessary
in the future not to mention the political risk as “right-wing
parties championing a less-Europe ticket still gather nearly 40%
of voting intention.”

Unicredit analysts sound more optimistic.

The next ratings action for Italy will be from Moody’s on
November 6. “I’m pretty sure they won’t change anything on that
occasion, but S&P has now taken the lead on how the rating
agencies will – read: should - look at Europe,” its chief
economist Erik F. Nielsen says in a research note.

“The SURE bond issue sends two very clear messages: there is
a huge demand for a euro-denominated safe asset and there is
strong confidence in the new and enhanced European project,”
according to co-head of the research team Luca Cazzulani.

(Stefano Rebaudo)

*****

EUROPE OPENS IN THE DARK, BUT THERE'S SOME LIGHT (0841 GMT)

Losses are almost everywhere at the start of trading in
Europe with SAP leading the way, down 19% and set for
its worst day in 24 years, after the region's biggest tech
company dumped its targets, underscoring the big risks that the
second COVID-19 wave poses to the economic and corporate
recovery.

All country benchmarks are showing heavy declines in early
deals as worries over surging Covid cases dominate, and only
healthcare is managing to post a small gain with AstraZeneca
up marginally after an upbeat Financial Times report
about the vaccine developed by the UK drugmaker and the
University of Oxford.

The newspaper said their vaccine produced a robust immune
response in elderly people, the group at highest risk. Even
though that's not the kind of vaccine breakthrough investors are
looking for, it's still an encouraging development that can
keeps markets afloat despite the fresh lockdown risks.

Here's your snapshot:

(Danilo Masoni)

*****

ON OUR RADAR: SAP NEEDS A VACCINE TOO (0727 GMT)

Downbeat virus developments and no progress in U.S. stimulus
talks are surely a downer this morning but corporate newsflow
isn't helping either.

Shares in German software maker SAP are down 13%
in premarket trade after Europe's largest IT group by market
capitalisation cut its guidance for the year and abandoned its
forecast that profitability would expand steadily over the
medium term, saying coronavirus lockdowns would hit demand well
into 2021.

There's virus pain also for French car rental company
Europcar, which dropped its 2020 financial outlook as
it posted a slump in its Q3 results, hit by the impact of the
COVID-19 crisis.

Meantime, Lufthansa shares are down 2.3% in
premarket after the German airline said it would ground more
planes during winter.

In dealmaking news, U.S. buyout group Carlyle Group
is nearing an agreement to acquire Siemens mechanical
drive arm Flender, for about for about 2 billion euros,
Bloomberg News reported citing sources.

Frozen bread maker Aryzta said on Saturday it had
concluded discussions with Elliott Advisors without a binding
takeover offer and that it would now look at other options.

Eyes also on UK banks after the Times newspaper reported
that local regulators are considering plans to allow lenders to
start paying dividends again next year.

On the Covid treatment front however there's some good
looking newsflow. The FT reported that early results from tests
for the vaccine being developed by the University of Oxford and
AstraZeneca, show it produces a robust immune response
in elderly people.

(Danilo Masoni)

*****

MORNING CALL: COVID RISK-OFF (0637 GMT)

European shares were set to start the week in a clear
risk-off mood as Covid infections are surging rapidly across the
region, prompting new social restrictions that could hurt the
economic recovery.

Over the weekend Spain imposed local nighttime curfews and
banning travel between regions in some cases, while Italy
ordered bars and restaurants to close early and shut public
gyms, cinemas and swimming pools.

France registered a record 52,010 new confirmed coronavirus
infections over the past 24 hours.

Meantime in the United States, which saw its highest ever
number of new COVID-19 cases in the past two days,
there was no clear progress on a stimulus package.

Euro STOXX 50 futures were last down 1%, DAX futures down
1.3% and FTSE futures down 0.6%.

(Danilo Masoni)

*****

More News
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.